Table 2.

Effect of FSK, Glibenclamide and Atorvastatin on serum creatinine, absolute kidney weight, kidney weight/body weight %, total renal collagen content and serum total cholesterol

Groups	Serum Creatinine (mg/dL)	Absolute Kidney Weight (g)	Kidney weight/Body weight %	Total Renal Collagen Content (mg/g)	Serum Total Cholesterol (mg/dL)
Normal Control	0.60 ± 0.12	0.42 ± 0.06	0.61 ± 0.04	2.32 ± 0.21	62.51 ± 6.79
FSK per se	0.58 ± 0.11	0.45 ± 0.11	0.58 ± 0.04	2.48 ± 0.24	60.18 ± 6.12
Diabetic Control	1.83 ± 0.07a	1.35 ± 0.09a	1.15 ± 0.06a	5.95 ± 0.35a	165.7 ± 6.77a
FSK-10 in Diabetic group	1.72 ± 0.07a	1.25 ± 0.06a	1.08 ± 0.06a	5.46 ± 0.27a	154.3 ± 8.93a
FSK-20 in Diabetic group	1.42 ± 0.06b	1.11 ±0.09b	1.01 ± 0.05b	4.82 ± 0.24b	127.9 ± 4.88b
FSK-30 in Diabetic group	1.05 ± 0.08b,c	0.93 ± 0.06b,c	0.90 ± 0.04b,c	3.94 ± 0.27b,c	108.0 ± 7.09b,c
Glibenclamide in Diabetic group	0.86 ± 0.06b,d	0.77 ± 0.07b,d	0.79 ± 0.05b,d	3.21 ± 0.30b,d	151.1 ± 7.73b
Atorvastatin in Diabetic group	1.61 ± 0.11b	1.13 ± 0.10b	0.99 ± 0.04b	4.55 ± 0.28b	84.55 ± 8.16b,d
Glibenclamide + FSK-30 in Diabetic group	0.69 ± 0.04b,e	0.61 ± 0.06b,e	0.69 ± 0.04b,e	2.74 ± 0.27b,e	103.1 ± 4.22b,e
Atorvastatin + FSK-30 in Diabetic group	0.98 ± 0.07b,f	0.80 ± 0.55b,f	0.81 ± 0.05b,f	4.08 ± 0.34b,f	69.78 ± 8.38b,f

Values are expressed as Mean ± SD (n = 7 per group).

^aP < 0.05 vs normal control, FSK per se group;

^bP < 0.05 vs diabetic control & FSK-10 mg/kg treated group;

^cP < 0.05 vs FSK-20 mg/kg treated group;

^dP < 0.05 vs FSK-30 mg/kg treated group;

^eP < 0.05 vs GB-0.6 mg/kg treated group;

^fP < 0.05 vs Atorvastatin-0.5 mg/kg treated group.